MARKETS / NYSE / MLSS
NYSE · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · SMALL CAP

Milestone Scientific Inc. MLSS

16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$9.0M
▲ 4.0% vs FY2024
EPS · FY25
$-0.07
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-132.4%
Net margin · FY25
-63.8%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 9.0M
Revenue, FY2025 · full 16-year series below
Revenue Net income
0.0040.0080.0120.0-0.0201020132016201920222025
0.0040.0080.0120.0-0.02016201920222025

The company lost 64 cents on every revenue dollar this year.

Per share
USD -0.07
Diluted EPS, FY2025
EPS
0.40.81.2-0.07201020132016201920222025
0.40.81.2-0.072016201920222025

The company pays no cash dividend.

Profitability
-132.4%
Return on equity, FY2025
ROE
10203040-132.4%201020132016201920222025
10203040-132.4%2016201920222025
Operating margin-63.5%
Net margin-63.8%
Return on assets-65.0%

Each USD of equity lost 132 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+10.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.6%
+10.5%
−0.6%
−0.6%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.08B
Shares outstanding, FY2025
0.010.08201020132016201920222025
0.030.082016201920222025
Change, 5 years+25.4%
Change, 10 years+271.0%

The share count grew 25% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 7.8M
total assets, end of FY2025
Total assetsUSD 7.8M
EquityUSD 2.8M
CashUSD 1.1M
Current ratio1.81×

Equity funds 36% of total assets.

History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.07
−0.06
·
·
−0.10
−0.12
−0.16
−0.21
−0.16
−0.22
−0.26
−0.08
0.08
−0.05
−0.10
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−132.4
−68.1
−76.0
−65.5
−41.9
−82.0
−465.1
−169.2
−65.9
−63.2
−43.8
−16.9
39.3
−44.9
−69.4
−26.3
Shares out B
0.08
0.08
0.08
0.07
0.07
0.06
0.05
0.03
0.03
0.03
0.02
0.02
0.02
0.02
0.02
0.01

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
63 of 63
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed